monoclonal antibody antibodies sars-cov-2 covid-19 coronavirus pandemic eli lilly receptor binding domain spike protein
First Antibody Trial Launched in COVID-19 Patients
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients

In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.

In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.

receptor binding sites
Learn About Sero-Surveillance During the COVID-19 Pandemic
Using Sero-Surveillance to Combat the COVID-19 Pandemic
The Scientist Creative Services Team and Bio-Rad Laboratories | Feb 7, 2022
Immunoassays for detecting, tracking, and testing SARS-CoV-2 antibody responses
Deep Pocket Exploration
Ruth Williams | Feb 1, 2017
A modification to traditional docking software enables the examination of a ligand’s passage into its receptor.
Yun “Nancy” Huang: Eager for Epigenetics
Amanda B. Keener | Aug 1, 2015
Assistant Professor, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston. Age: 35